 | Up a level |
Terwijn, M.; van Putten, W. L. J.; Kelder, A.; van der Velden, V. H. J.; Brooimans, R. A.; Pabst, T.; Maertens, J.; Boeckx, N.; de Greef, G. E.; Valk, P. J. M.; Preijers, F. W. M. B.; Huijgens, P. C.; Drager, A. M.; Schanz, U.; Jongen-Lavrecic, M.; Biemond, B. J.; Passweg, J. R.; van Gelder, M.; Wijermans, P.; Graux, C.; ... (2013). High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. Journal of clinical oncology, 31(31), pp. 3889-3897. American Society of Clinical Oncology 10.1200/JCO.2012.45.9628
Von Rohr, A.; Schmitz, S.-F. H.; Tichelli, A.; Hess, U.; Piguet, D.; Wernli, M.; Frickhofen, N.; Konwalinka, G.; Zulian, G.; Ghielmini, M.; Rufener, B.; Racine, C.; Fey, M. F.; Cerny, T.; Betticher, D.; Tobler, A. (2002). Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology, 13(10), pp. 1641-1649. Oxford University Press 10.1093/annonc/mdf272
Betticher, D. C.; Ratschiller, D.; Hsu Schmitz, S.-F.; Von Rohr, A.; Hess, U.; Zulian, G.; Wernli, M.; Tichelli, A.; Tobler, A.; Fey, M. F.; Cerny, T. (1998). Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Annals of oncology, 9(7), pp. 721-726. Oxford University Press 10.1023/A:1008273131598
